olfactory receptor family 7 subfamily E member 21 pseudogeneGenealiases: OR4DG · OR7E127P · OR7E141P · OR7E142P · OR7E49P · OST035
Q-omics provides the consensus-scored OR7E21P profile across patient tissues and cancer cell-line models. OR7E21P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR7E21P is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, OR7E21P RNA expression shows 5,482 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUAD, and STAD as cancer lineages where OR7E21P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E21P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E21P survival associations across molecular data types. OR7E21P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E21P RNA expression–survival associations across cancer types. High OR7E21P expression shows unfavorable associations in ACC, MESO, UCEC, DLBC, PCPG and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR7E21P RNA expression.
This table summarizes OR7E21P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E21P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E21P shows higher tumor expression in LUAD and LUSC. The LUAD box plot shows higher OR7E21P RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .021).
This table shows molecular features associated with OR7E21P in patient tissues and cancer cell lines. In patient samples, OR7E21P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
